Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07205900 · ClinicalTrials.gov registry record · Phase 2

Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus

A Phase 2 study of Obesity and Obese, sponsored by Hanmi Pharmaceutical Company Limited.

Recruiting
Registry status
Phase 2
Development phase
250
Enrollment target
13
Study locations

NCT07205900 is a Phase 2 study of Obesity and Obese that is actively recruiting participants, run by Hanmi Pharmaceutical Company Limited. The registered enrollment target is 250 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (69% lower). The trial reports 13 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07205900, a Phase 2 study of Obesity and Obese, is actively recruiting participants, sponsored by Hanmi Pharmaceutical Company Limited.

RECRUITING
Registry status
Phase 2
Development phase
250 participants
Enrollment target
13
Study locations

Study Summary

This Study is a Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of HM15275 for 36 Weeks in Obese or Overweight Subjects Without Diabetes Mellitus.

Conditions Studied

Obesity Obese

Interventions

  • DRUG HM15275
  • DRUG Placebo of HM15275

Study Locations (13)

North Carolina

  • Accellacare of Cary - Cary Medical Group - Cary
  • Accellacare of Hickory - Hickory
  • Raleigh Medical Group, P.A. - Raleigh
  • Accellacare of Piedmont - Piedmont HealthCare - Statesville
  • Accellacare of Wilmington, LLC - Wilmington
  • Accellacare of Winston Salem - Winston-Salem

Tennessee

  • Accellacare of Bristol-PAC of Tennessee - Bristol
  • Bristol-Internal Medicine and Pediatric Associates of Bristol, P.C. - Bristol

California

  • ProSciento Inc - Chula Vista

Illinois

  • Accellacare of Duly - Duly Oak Lawn - Oak Lawn

Iowa

  • Accellacare of McFarland - Ames

South Carolina

  • Accellacare of Charleston - Mt. Pleasant

Texas

  • Velocity Clinical Research, Dallas - Dallas

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2025-12-02
Est. Completion 2027-01
Phase Phase 2

Sponsor

Hanmi Pharmaceutical Company Limited

25 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07205900

The ClinicalTrials.gov registry entry for NCT07205900 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (69% lower). The listed sponsor is Hanmi Pharmaceutical Company Limited, which has 25 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which HM15275 is the first listed.

NCT07205900 reports 13 study locations spanning 7 distinct geographic areas - top geographies include North Carolina, Tennessee, California.

Frequently Asked Questions

What is clinical trial NCT07205900 about?

NCT07205900 is a clinical study titled "Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus". This Study is a Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of HM15275 for 36 Weeks in Obese or Overweight Subjects Without Diabetes Mellitus.

What is the current status of trial NCT07205900?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 2025-12-02. Estimated completion is 2027-01.

What conditions does trial NCT07205900 study?

This clinical trial studies the following conditions: Obesity, Obese.

What interventions are being tested in trial NCT07205900?

The interventions under investigation include: HM15275 (DRUG), Placebo of HM15275 (DRUG).

Who is sponsoring clinical trial NCT07205900?

This trial is sponsored by Hanmi Pharmaceutical Company Limited, which has 25 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07205900 being conducted?

This trial has 13 study locations across California, Illinois, Iowa, North Carolina, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Obesity

All registered trials for this condition

Obese

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.